Hyperinflation refers to the lung’s increase in size due to the trapped air that has caused them to expand. The BREATHE-3 trial uses self-expanding nitinol airway scaffolds that are placed ...

NORTH PHILADELPHIA (WPVI) -- There's a potential new treatment for severe emphysema, and Philadelphia is a key test site for this small device with big potential to improve lives. In COPD (Chronic ...

Men and women with chronic obstructive pulmonary disease (COPD), bronchiectasis, and nontuberculous mycobacterial (NTM) lung disease report differences in symptoms, mental health, disease burden, and ...

Please provide your email address to receive an email when new articles are posted on . Adults with a low-dose CT scan between June 2000 and December 2008 were followed for a median of 23.3 years.

Overall survival probabilities were similar for the IPF-only and IPF with emphysema groups (43.2% vs 42.3%, P =.7) Patients with idiopathic pulmonary fibrosis (IPF) only and those who had IPF and ...

Emphysema detected on baseline low-dose chest CT (LDCT) in the lung cancer screening cohort of more than 9,000 asymptomatic adults was associated with death from all causes, chronic obstructive ...

Please provide your email address to receive an email when new articles are posted on . A variety of options/tools are needed when treating patients with severe emphysema and breathlessness. A phase 3 ...

Emphysema detected on baseline low-dose chest CT (LDCT) in the lung cancer screening cohort of more than 9,000 asymptomatic adults was associated with death from all causes, chronic obstructive ...

Visually assessed pulmonary emphysema independently predicted modestly elevated all-cause mortality risk over 25 years of follow-up in patients with a history of smoking. After controlling for other ...

OAK BROOK, Ill. – Emphysema detected on baseline low-dose chest CT (LDCT) in the lung cancer screening cohort of more than 9,000 asymptomatic adults was associated with death from all causes, chronic ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Apreo Health, a clinical-stage medical device company pioneering a novel, tissue-sparing approach for treating severe emphysema, today announced that the first ...

After emerging from stealth earlier this year, Apreo Health has raised $130 million to breathe new life into the development of lung implants for emphysema. The financing comes through a series B ...